ATS 2019 Virtual Final Program

3:45 3 Year Old with Anemia and Respiratory Distress B. Mahmood, MD, Dallas, TX 4:10 Expert Discussant D. Simon, MD, Atlanta, GA CLINICAL CRITICAL CARE TRACK CME Credits Available: 2 C84 CLINICAL TRIALS IN THE CRITICALLY ILL: ECMO AS A CAUTIONARY TALE Assemblies on Critical Care; Clinical Problems; Nursing 2:15 p.m. - 4:15 p.m. OMNI DALLAS DOWNTOWN Dallas Ballroom D/H (Level 3) Target Audience Adult and pediatric critical care clinicians and researchers Objectives At the conclusion of this session, the participant will be able to: • incorporate lessons and perceptions from survivors of ARDS; • learn about the challenges of designing clinical trials of complex interventions in the critically ill, and learn novel strategies for future evaluations of these interventions; • gain new strategies for the evidence-based management of patients with severe ARDS. This session will provide an overview of the challenges in conducting clinical trials in critically ill patients, using recent trials on VV ECMO in severe ARDS as an example. The session incorporates 10 brief presentations highlighting key issues and insights related to clinical trial design, implications for clinical practice, and future ICU research followed by a panel Q&A discussion. Chairing: E. Fan, MD, PhD, Toronto, Canada C.T.L. Hough, MD, MSc, Seattle, WA 2:15 Patient Perspective on ECMO for Severe ARDS E. Rubin, JD, Northbrook, IL 2:20 VV ECMO: Ready for Primetime! A. Combes, MD, PhD, Paris, France 2:30 VV ECMO for ARDS: Not So Sure ... M.N. Gong, MS, MD, Bronx, NY 2:40 How Should We Interpret “Negative Trials” in 2019? A.J. Walkey, MD, MSc, Boston, MA 2:50 How Do We Prepare Clinicians To Deliver ECMO? J.H. Badulak, MD, Seattle, WA 3:00 How Should We Design the Next ECMO Trial? E. Fan, MD, PhD, Toronto, Canada 3:10 What Are the Right Outcomes to Study in ECMO Trials? C.T.L. Hough, MD, MSc, Seattle, WA 3:20 Is There a Role for Precision Medicine? C.S. Calfee, MD, San Francisco, CA 3:30 What’s in the Pipeline for Extracorporeal Support in ARDS D. Brodie, MD, New York, NY 3:40 OK, So What Now? S.S. Carson, MD, Chapel Hill, NC 3:55 Panel Q&A C.T.L. Hough, MD, MSc, Seattle, WA BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C85 SCIENTIFIC BREAKTHROUGHS IN LUNG BIOLOGY Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Respiratory Structure and Function 2:15 p.m. - 4:15 p.m. KBHCCD Ballroom D Two (Level 3) Target Audience Basic and translational scientists, physicians, and trainees Objectives At the conclusion of this session, the participant will be able to: • describe the latest scientific advances in basic and translational science; • utilize novel techniques and approaches to the study of lung development and disease; • apply knowledge from basic and translational research towards development of novel therapeutic strategies. This session will focus on recent high impact discoveries and novel approaches to study of lung development and diseases. This session will span basic biology to cutting edge therapeutics. Presentations from experts in the field will be complemented by abstract presentations related to the topic being discussed. Chairing: L.R. Young, MD, ATSF, Nashville, TN E.R. Neptune, MD, Baltimore, MD 2:15 Introduction to Scientific Breakthroughs Session L.R. Young, MD, ATSF, Nashville, TN 2:16 Advances in Human Lung Stem Cell Organoids T. Desai, MD, MPH, Stanford, CA 2:39 The Driving FORCE in Alveolar Regeneration and Diseases N. Tang, PhD, Beijing, China 3:03 New Concepts in Surfactant Homeostasis B.C. Trapnell, MD, Cincinnati, OH 3:27 Reducing Protein Oxidation Reverses Lung Fibrosis in Multiple Pre-Clinical Models Y.M.W. Janssen-Heininger, PhD, Burlington, VT 3:51 Neutrophil Exosomes Are Novel Pathogenic Entities in COPD A. Gaggar, MD, PhD, Birmingham, ALT ATS 2019 • Dallas, TX 292 TUESDAY • MAY 21